September 2 - 5, 2021 Virtual Conference
|Temporal and Spatial Dynamics of Hepatic Stellate Cell Activation in Intrahepatic Cholangiocarcinoma
|Intra-tumoral epigenetic heterogeneity and aberrant molecular clocks in hepatocellular carcinoma
|Autoimmunity and cancer immunosurveillance in the biliary tree
|Inflamed class of HCC: an expansion of the immune class based upon new molecular features
|Josep M. Llovet
|Phenotypic characteristics of the tumour microenvironment in primary and secondary hepatocellular carcinoma.
|New therapeutic targets in cisplatin-resistant hepatoblastoma
|Notch Pathway Activation Drives Immune Evasion in Hepatocellular Carcinoma
|Deep sequencing of HCC endothelium reveals an active role in immunosuppression and highlights the ectonucleotidase CD73 as a potential therapeutic target.
|Activating Mucosal-Associated Invariant T cells (MAITs) in vivo as a Novel Target for Liver Cancer Immunotherapy
|The TUMOR SUPPRESOR ROLE OF THE a1-Na/K-ATPase/Src-p/PI3K SIGNALOSOME in NASH Related Hepatocellular Carcinoma: A TRANSLATIONAL STUDY.
|Interplay between EZH2 and OGT in hepatocellular carcinoma
|Molecular characterization of HCC in Mongolia delineates unique genomic features
|Exogenous Antioxidants, N-acetylcysteine and Glutathione, Enhance Cancer Initiation and Growth in Hepatocellular Carcinoma
|Vanilla Xin Zhang
|Dual mechanisms mediated by specific transcription factors and RalGAPA2 activates RalA signaling to support HCC development
|Trans-arterial chemoembolization as a loco-regional inducer of immunogenic cell death in hepatocellular carcinoma: implications for immunotherapy.
|Portal vein thrombosis in HCC patients infected with COVID-19
|Identification of IGF2 as genomic driver and actionable therapeutic target in hepatoblastoma
|Characteristics and survival of hepatocellular carcinoma in non-cirrhotic liver: A Spanish multicentre study
|PROGNOSIS OF PATIENTS WITH OTHER PRIMARY TUMORS ASSOCIATED TO HEPATOCELULLAR CARCINOMA.
|Geographic, linguistic, and cultural factors are associated with clinical presentation, receipt of treatment, and survival of patients with hepatocellular carcinoma
|Hepatic elastometry and risk of recurrence after HCC resection
|Association of whole grains and dietary fiber intake with risk of liver cancer and chronic liver diseases in the NIH-AARP Diet and Health Study
|Gene Set adaptation through graph generation enhances signature discrimination power and validates metabolism-related prognostic signatures in Hepatocellular Carcinoma
|EXTERNAL VALIDATION OF THE INTEGRATED LIVER INFLAMMATORY SCORE (ILIS) AS A PROGNOSTIC INDEX IN PATIENTS WITH HEPATOCELLULAR CARCINOMA
|Undernutrition in patients with primary hepatocellular carcinoma
|Dual filtration system for isolation and single cell RNA sequencing of circulating tumor cells and clusters in hepatocellular carcinoma: a pilot study
|The systemic inflammatory response identifies patients with adverse clinical outcome from immunotherapy in hepatocellular carcinoma.
|Clinicopathological characterization of steatohepatitic variant of hepatocellular carcinoma (SH-HCC).
|Sorafenib in extended patient populations in real-world clinical practice: Baseline characteristics from OPTIMIS and GIDEON
|The Efficacy and Prognostic Factors of TACE Combined with Apatinib in the Treatment of BCLC stage C Hepatocellular Carcinomas
|A Pilot Study of the combination of Immune Checkpoint Inhibition with Ablation in Subjects with Hepatocellular Carcinoma; an evaluation of Trans-arterial Chemoembolization (TACE) and Radiofrequency Ablation (RFA)
|A phase Ib study of pembrolizumab following trans-arterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): PETAL.
|Impact of metabolic syndrome and non-alcoholic fatty liver disease in outcomes and tolerance after percutaneous multibipolar radiofrequency ablation for early hepatocellular carcinoma
|Thi Thu Nga Nguyen
|Early antibiotic exposure is not detrimental to response to immune checkpoint inhibitor therapy for hepatocellular carcinoma: evidence from an observational study.
|Selective Internal Radiation Therapy with Yttrium-90 Resin Microspheres followed by Gemcitabine plus Cisplatin for Treatment of Intra-hepatic Cholangiocarcinoma: A Phase 2 Single-Arm Multicenter Clinical Trial
|Stephen Lam CHAN
|The Number of Small Hepatocellular Carcinoma Nodules in Patients Listed for Liver Transplantation within the Alpha-Fetoprotein Score Is a Prognostic Risk Factor
|Real-world outcomes of patients with hepatocellular carcinoma treated with transarterial radioembolization: results from CIRT, a large European prospective multi-centre observational study
|Exploratory Network Meta-analyses of Selective Internal Radiation Therapy versus Sorafenib, Lenvatinib, and Atezolizumab-Bevacizumab as First-line Treatment in Subgroups of Patients with Hepatocellular Carcinoma
|Previous/Concurrent Radiation Enhanced the Efficacy of Immunotherapy in Metastatic and Recurrent Liver Cancer: A Pilot Study from the Real-world Data
|Progression patterns and clinical outcomes following immune checkpoint inhibition for hepatocellular carcinoma (HCC): a multi-institutional international study.
|Identification of Regorafenib Prognostic index (REP index) via recursive partitioning analysis in Advanced Hepatocellular Carcinoma Patients Receiving systemic treatment.
|Impact of previous surgery on prognosis in patients with cholangiocarcinoma under chemotherapy
|Free Androgen Index Levels May Influence the Trans-arterial Chemoembolization with Doxorubicin-Eluting Beads Response in Hepatocellular Carcinoma Patients: Preliminary Results.
|A humanized Claudin-1-specific monoclonal antibody for treatment of hepatocellular carcinoma
|Emerging role of circulating miR-23b-3p and tissue miR-193a-3p as potential innovative biomarkers for human hepatocellular carcinoma.
|Lifestyle changes in DAA-cured Hepatitis C patients with advanced liver disease included in a nurse-led liver cancer screening program
|Early SARS-CoV-2-related mortality of liver cancer patients: Cancer stage matters.
|Deciphering Liver Cancer Tissue Organization by 3D Electron Microscopy and machine learning
|Low baseline plasma L-Glutamine concentration identifies hepatocellular carcinoma patients at high risk of developing early gastrointestinal adverse events during sorafenib treatment.
|Efficacy and Safety of Lenvatinib in Patients with Recurrent Hepatocellular Carcinoma after Liver Transplantation: A Retrospective Analysis
|Novel management score of systemic therapy for hepatocellular carcinoma patients
September 2 - 5, 2021 Virtual Conference